Table 3. Related metabolites that exist at abnormal levels in the urine from IgAN patients.
| potential biomarkers | RT | VIP | P | FC |
|---|---|---|---|---|
| 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(trimethylsilyl)- | 17.8 | 2.06063 | 0.001257 | 1.021583 |
| Carbon disulfide | 1.475 | 11.7166 | 2.82E-05 | 0.309181 |
| Carbamic acid, monoammonium salt | 1.141667 | 4.30661 | 0.000711 | 0.198104 |
| 2-Benzofurancarboxylic acid, 7-methoxy-, (3,4,4-trimethyl-1,2-dioxetan-3-yl)methyl ester | 1.35 | 2.64804 | 0.000126 | −0.17541 |
| 4-Heptanone | 5.475 | 2.54699 | 0.000442 | −0.33223 |
| Pyrrole | 3.075 | 2.88632 | 8.47E-05 | −0.56124 |
| 2-Pentanone | 2.3 | 5.40358 | 0.000347 | −0.62353 |
Abbreviations: RT, retention time; VIP, variable importance in the projection; FC, fold change, defined as: FC = log10(X2/X1), while X1 denoted the arithmetic mean value of certain metabolite in the control group and X2 denoted the arithmetic mean value in the case group. FC with a positive value indicates that the concentration of certain metabolite is relatively higher in IgAN patients compared with healthy controls. FC with a negative value indicates that the concentration of certain metabolite is relatively lower in IgAN patients compared with healthy controls.